Communiqués Zura Bio Limited

Actions

ZURA

KYG9TY5A1016

Temps réel estimé Cboe BZX Autres places de cotation 16:50:32 16/07/2024			Varia. 5j.	Varia. 1 janv.
3,91 ^USD	+5,39 %		+3,06 %	-20,56 %

14/06	Zura Bio présente des données sur le programme Tibulizumab (Zb-106) à Eular 2024	CI
06/06	Zura Bio Limited annonce la formation d'un conseil consultatif scientifique	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation	15/07	AQ
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation	12/07	BU
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024	14/06	BU
Zura Bio : Phase 1 Clinical Trial Evaluating the Pharmacokinetics and Pharmacodynamics of a Novel IL-17A and BAFF Dual Antagonist in Sjogren’s Syndrome	14/06	PU
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology	06/06	BU
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024	03/06	BU
Zura Bio Announces Participation in June Investor Conferences	29/05	BU
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05	BU
Zura Bio Announces Oversubscribed $112.5 Million Private Placement	18/04	BU
Zura Bio Announces Robert Lisicki as CEO and Director	08/04	BU
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer	28/03	BU
Zura Bio Announces Participation at March Conferences	04/03	BU
Zura Bio Announces Participation at February Investor Conferences	02/02	BU
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO	08/01	BU
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit	03/01	BU
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok	04/12	BU
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors	14/11	BU
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights	13/11	BU
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute	12/09/23	BU
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights	14/08/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Zura Bio Limited

Actions

ZURA

KYG9TY5A1016

Communiqués

Filtres